Mechanism of action of the anti-cancer agent, triptolide

Veena Sangwan, Ashok Saluja

Research output: Chapter in Book/Report/Conference proceedingChapter

4 Citations (Scopus)

Abstract

Triptolide, a dipertene triepoxide isolated from the roots of the Chinese herb Tripterygium wilfordii Hook F., is a promising anti-cancer agent. While its role as a promoter of cell death, both in vivo and in vitro, in various cancers is well established, the mechanism by which it induces cell death in cancer cells is not well understood, and has therefore been the subject of intense interest in the past decade. Studies to date have shown that triptolide acts in a pleiotropic fashion, resulting in decrease of HSP70 expression, affecting calcium release, causing lysosomal membrane depolarization, inhibiting NFκB activity, iNOS and Cox-2 expression, as well as acting as a transcription inhibitor and an anti-angiogenesis factor. In this review, we discuss the possible modes of action of triptolide in various cancers, as well as a novel compound derived from triptolide currently being prepared for Phase I clinical trials.

Original languageEnglish (US)
Title of host publicationNutraceuticals and Cancer
PublisherSpringer Netherlands
Pages135-150
Number of pages16
Volume9789400726307
ISBN (Electronic)9789400726307
ISBN (Print)9400726295, 9789400726291
DOIs
StatePublished - Dec 1 2012
Externally publishedYes

Fingerprint

Neoplasms
Cell Death
Tripterygium
Clinical Trials, Phase I
Angiogenesis Inhibitors
Calcium
Membranes
triptolide
In Vitro Techniques

Keywords

  • Calcium
  • Cancer
  • Cox-2
  • HSP70
  • iNOS
  • Lysosome
  • NFκB
  • Triptolide

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sangwan, V., & Saluja, A. (2012). Mechanism of action of the anti-cancer agent, triptolide. In Nutraceuticals and Cancer (Vol. 9789400726307, pp. 135-150). Springer Netherlands. https://doi.org/10.1007/978-94-007-2630-7_7

Mechanism of action of the anti-cancer agent, triptolide. / Sangwan, Veena; Saluja, Ashok.

Nutraceuticals and Cancer. Vol. 9789400726307 Springer Netherlands, 2012. p. 135-150.

Research output: Chapter in Book/Report/Conference proceedingChapter

Sangwan, V & Saluja, A 2012, Mechanism of action of the anti-cancer agent, triptolide. in Nutraceuticals and Cancer. vol. 9789400726307, Springer Netherlands, pp. 135-150. https://doi.org/10.1007/978-94-007-2630-7_7
Sangwan V, Saluja A. Mechanism of action of the anti-cancer agent, triptolide. In Nutraceuticals and Cancer. Vol. 9789400726307. Springer Netherlands. 2012. p. 135-150 https://doi.org/10.1007/978-94-007-2630-7_7
Sangwan, Veena ; Saluja, Ashok. / Mechanism of action of the anti-cancer agent, triptolide. Nutraceuticals and Cancer. Vol. 9789400726307 Springer Netherlands, 2012. pp. 135-150
@inbook{b402e9084e5d429ab134298831a8b39d,
title = "Mechanism of action of the anti-cancer agent, triptolide",
abstract = "Triptolide, a dipertene triepoxide isolated from the roots of the Chinese herb Tripterygium wilfordii Hook F., is a promising anti-cancer agent. While its role as a promoter of cell death, both in vivo and in vitro, in various cancers is well established, the mechanism by which it induces cell death in cancer cells is not well understood, and has therefore been the subject of intense interest in the past decade. Studies to date have shown that triptolide acts in a pleiotropic fashion, resulting in decrease of HSP70 expression, affecting calcium release, causing lysosomal membrane depolarization, inhibiting NFκB activity, iNOS and Cox-2 expression, as well as acting as a transcription inhibitor and an anti-angiogenesis factor. In this review, we discuss the possible modes of action of triptolide in various cancers, as well as a novel compound derived from triptolide currently being prepared for Phase I clinical trials.",
keywords = "Calcium, Cancer, Cox-2, HSP70, iNOS, Lysosome, NFκB, Triptolide",
author = "Veena Sangwan and Ashok Saluja",
year = "2012",
month = "12",
day = "1",
doi = "10.1007/978-94-007-2630-7_7",
language = "English (US)",
isbn = "9400726295",
volume = "9789400726307",
pages = "135--150",
booktitle = "Nutraceuticals and Cancer",
publisher = "Springer Netherlands",

}

TY - CHAP

T1 - Mechanism of action of the anti-cancer agent, triptolide

AU - Sangwan, Veena

AU - Saluja, Ashok

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Triptolide, a dipertene triepoxide isolated from the roots of the Chinese herb Tripterygium wilfordii Hook F., is a promising anti-cancer agent. While its role as a promoter of cell death, both in vivo and in vitro, in various cancers is well established, the mechanism by which it induces cell death in cancer cells is not well understood, and has therefore been the subject of intense interest in the past decade. Studies to date have shown that triptolide acts in a pleiotropic fashion, resulting in decrease of HSP70 expression, affecting calcium release, causing lysosomal membrane depolarization, inhibiting NFκB activity, iNOS and Cox-2 expression, as well as acting as a transcription inhibitor and an anti-angiogenesis factor. In this review, we discuss the possible modes of action of triptolide in various cancers, as well as a novel compound derived from triptolide currently being prepared for Phase I clinical trials.

AB - Triptolide, a dipertene triepoxide isolated from the roots of the Chinese herb Tripterygium wilfordii Hook F., is a promising anti-cancer agent. While its role as a promoter of cell death, both in vivo and in vitro, in various cancers is well established, the mechanism by which it induces cell death in cancer cells is not well understood, and has therefore been the subject of intense interest in the past decade. Studies to date have shown that triptolide acts in a pleiotropic fashion, resulting in decrease of HSP70 expression, affecting calcium release, causing lysosomal membrane depolarization, inhibiting NFκB activity, iNOS and Cox-2 expression, as well as acting as a transcription inhibitor and an anti-angiogenesis factor. In this review, we discuss the possible modes of action of triptolide in various cancers, as well as a novel compound derived from triptolide currently being prepared for Phase I clinical trials.

KW - Calcium

KW - Cancer

KW - Cox-2

KW - HSP70

KW - iNOS

KW - Lysosome

KW - NFκB

KW - Triptolide

UR - http://www.scopus.com/inward/record.url?scp=84928884201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928884201&partnerID=8YFLogxK

U2 - 10.1007/978-94-007-2630-7_7

DO - 10.1007/978-94-007-2630-7_7

M3 - Chapter

SN - 9400726295

SN - 9789400726291

VL - 9789400726307

SP - 135

EP - 150

BT - Nutraceuticals and Cancer

PB - Springer Netherlands

ER -